Arbeter A M, Starr S E, Weibel R E, Neff B J, Plotkin S A
Pediatrics. 1983 Mar;71(3):307-12.
The KMcC strain of live, attenuated varicella-zoster virus vaccine was studied in healthy children as a preliminary step toward varicella vaccine studies with this strain in children with leukemia. Forty-three children were immunized: 26 with the 40th passage vaccine and 17 with the 50th passage. Studies included surveillance for clinical reactivity, oropharyngeal excretion of vaccine virus, viruria, and viremia. Antibody responses were assayed by fluorescent antibody to membrane antigens and immune adherence hemagglutination. Cell-mediated immune responses were assayed by lymphocyte proliferation to varicella-zoster virus specific antigens. There was 100% seroconversion to the KMcC passage 40 and 50 vaccines (by fluorescent antibody to membrane antigen assay). Every child studied developed in vitro lymphocyte proliferation to varicella-zoster virus antigens. Papular skin lesions, probably vaccine related, occurred in 31% of the 40th passage vaccinees but in only 6% of the 50th passage vaccinees. The 50th passage KMcC strain vaccine is sufficiently immunogenic and safe to initiate clinical studies with leukemia patients.
对健康儿童研究了减毒活水痘-带状疱疹病毒KMcC株疫苗，以此作为在白血病患儿中用该毒株进行水痘疫苗研究的初步步骤。43名儿童接受了免疫接种：26名接种第40代疫苗，17名接种第50代疫苗。研究包括监测临床反应性、疫苗病毒的口咽排泄、病毒尿和病毒血症。通过膜抗原荧光抗体法和免疫黏附血凝试验检测抗体反应。通过对水痘-带状疱疹病毒特异性抗原的淋巴细胞增殖试验检测细胞介导的免疫反应。第40代和第50代KMcC株疫苗的血清转化率均为100%（通过膜抗原荧光抗体试验）。每个接受研究的儿童均出现了针对水痘-带状疱疹病毒抗原的体外淋巴细胞增殖。第40代疫苗接种者中31%出现了可能与疫苗相关的丘疹性皮肤损害，但第50代疫苗接种者中仅6%出现。第50代KMcC株疫苗具有足够的免疫原性且安全，可启动对白血病患者的临床研究。
